Want to see AU:IBX full AI Analyst Report?
IBX Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.06
Previous CloseN/A
Volume1.04M
Average Volume (3M)1.31M
Market Cap
AU$6.41M
Enterprise ValueAU$7.55
Total Cash (Recent Filing)AU$32.46K
Total Debt (Recent Filing)AU$2.19M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Feb 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding801,006,900
10 Day Avg. Volume1,829,881
30 Day Avg. Volume1,314,742
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.21
Price to Sales (P/S)0.00
P/FCF Ratio-1.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Targeted Cancer-imaging PlatformThe MagSense® platform is focused on molecular cancer imaging, including earlier detection and disease characterization. A targeted diagnostic approach could support differentiated clinical applications if development succeeds, giving the company a defined technology focus rather than an unfocused research portfolio.
Strong Gross Margin PotentialThe approximately 85% gross margin reported in 2024 indicates that the underlying technology may have attractive economics once commercial scale and revenue are established. This provides potential operating leverage, although current losses show that gross margin alone has not yet offset development and commercialization costs.
Improving Cash OutflowThe smaller free-cash-flow outflow in 2025 suggests some progress in controlling cash consumption compared with the prior year. If maintained, tighter cash use could extend funding runway and allow more resources to remain focused on advancing the diagnostic platform toward commercialization.
Bears Say
No Reported Revenue In 2025Revenue falling to zero in 2025 demonstrates that the company has not yet established a dependable commercial revenue base. Without recurring operating inflows, funding for research, regulatory progress, and commercialization remains dependent on external capital or further balance-sheet resources.
Persistent UnprofitabilityPersistent operating and net losses show that the business has not achieved sufficient scale to cover its ongoing R&D and commercialization costs. Continued losses can constrain strategic flexibility, increase financing needs, and delay the point at which the platform can support itself through operations.
Negative Equity And Financial StressNegative equity combined with meaningful debt indicates limited balance-sheet resilience and a reduced cushion against further losses. This financial structure can restrict flexibility to fund development, heighten dependence on additional financing, and make sustained execution more difficult over the medium term.
Imagion Biosystems Ltd. News
IBX FAQ
What was Imagion Biosystems Ltd.’s price range in the past 12 months?
Imagion Biosystems Ltd. lowest share price was AU$0.01 and its highest was AU$0.06 in the past 12 months.
What is Imagion Biosystems Ltd.’s market cap?
Imagion Biosystems Ltd.’s market cap is AU$6.41M.
When is Imagion Biosystems Ltd.’s upcoming earnings report date?
Imagion Biosystems Ltd.’s upcoming earnings report date is Feb 26, 2027 which is in 163 days.
How were Imagion Biosystems Ltd.’s earnings last quarter?
Imagion Biosystems Ltd. released its earnings results on Aug 24, 2026. The company reported -AU$0.004 earnings per share for the quarter.
Is Imagion Biosystems Ltd. overvalued?
According to Wall Street analysts Imagion Biosystems Ltd.’s price is currently Overvalued.
Does Imagion Biosystems Ltd. pay dividends?
Imagion Biosystems Ltd. does not currently pay dividends.
What is Imagion Biosystems Ltd.’s EPS estimate?
Imagion Biosystems Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Imagion Biosystems Ltd. have?
Imagion Biosystems Ltd. has 801,006,900 shares outstanding.
What happened to Imagion Biosystems Ltd.’s price movement after its last earnings report?
Imagion Biosystems Ltd. reported an EPS of -AU$0.004 in its last earnings report. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Imagion Biosystems Ltd.?
Currently, no hedge funds are holding shares in AU:IBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imagion Biosystems Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:IBX Sentiment 81%
Sector Average 62%
Sector Average 62%
Insider Transactions
Bought Shares
Worth AU$75.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-27.94%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Imagion Biosystems Ltd.
Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic resonance; and cancer diagnostics businesses. It develops MagSense, which is in Phase 2 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to magnetic relaxometry. The company has collaboration agreement with Wayne State University to develop optimised MRI sequences which is in Phase 2 study of for the MagSense imaging agent. Imagion Biosystems Limited was incorporated in 2016 and is based in Melbourne, Australia.
Technical Analysis
―
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Genetic Signatures Ltd.
―
Integral Diagnostics Ltd.
―